NCT00409851已完成3 期
A 52 Week, Open Label Extension to the Randomized, Double-blind, Multicenter, Multifactorial, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Valsartan and Amlodipine Combined and Alone in Hypertensive Patients.
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 1,293
- 试验地点
- 3
- 主要终点
- Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough.
研究概览
简要总结
A ONE YEAR SAFETY STUDY FOR PATIENTS WHO COMPLETE STUDY VAA489A2201.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •SUCCESSFUL COMPLETION OF VAA489A2201 CORE TRIAL
- •VISIT 7 BLOOD PRESSURE MUST BE MSDBP ≤ 95 mmHg AND MSSBP ≤ 150 mmHg
排除标准
- •PATIENTS WHO EXPERIENCED ANY ADVERSE EVENTS CONSIDERED SERIOUS AND DRUG RELATED IN VAA489A2201 CORE
- •Other protocol-defined exclusion criteria may apply
结局指标
主要结局
Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough.
次要结局
- Change from baseline (Visit 2) in mean sitting systolic blood pressure at trough
- Change from baseline (Visit 2) in standing diastolic and systolic blood pressure at trough
- Sitting and standing pulse
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With HypertensionHYPERTENSIONNCT00170976Novartis403
Enrolling By Invitation
3 期
An Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia GravisGeneralized Myasthenia GravisNCT06435312UCB Biopharma SRL8
已完成
3 期
Fifty Two Week Extension Trial of Org 50081 (Esmirtazapine) in the Treatment of Insomnia (P05708)InsomniaNCT00610675Merck Sharp & Dohme LLC346
终止
2 期
BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)Rheumatoid ArthritisNCT00523328Biogen72
已完成
3 期
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With HypertensionHypertensionNCT00326768Boehringer Ingelheim184